Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CorMedix Inc. (CRMD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering a detailed view of its financial condition, governance, and material events. CorMedix is a Nasdaq Global Market–listed biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases, including DefenCath for catheter-related bloodstream infection prevention and a portfolio of anti-infective and hospital products acquired through Melinta Therapeutics LLC.
Current reports on Form 8-K document significant developments such as the completion of the Melinta acquisition, the related contingent payment and registration rights agreements, the issuance of convertible senior notes, equity offerings, and preliminary or final quarterly results. For example, a Form 8-K filed on November 12, 2025 furnishes third-quarter 2025 financial results and guidance updates, while earlier 8-Ks describe the Melinta transaction terms and the convertible notes offering used in part to fund the deal.
Proxy statements on Schedule 14A provide insight into CorMedix’s corporate governance and capital structure decisions. A definitive proxy statement filed in October 2025 outlines proposals for a special meeting, including amendments to the company’s stock incentive plan, ratification of certificate of designation amendments, and changes to its certificate of incorporation affecting preferred stock voting rights.
Investors can also use this page to access periodic reports referenced in the company’s proxy and 8-K filings, which contain audited financial statements, risk factors, and management’s discussion and analysis. These filings explain how CorMedix reports revenue from DefenCath and the Melinta portfolio, records goodwill and intangible assets, and accounts for items such as deferred tax assets and non-GAAP measures like adjusted EBITDA.
In addition, insider and capital markets–related filings are available, including disclosures about equity offerings, convertible notes, and voting results from annual and special meetings. Stock Titan’s interface pairs these documents with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q, 8-K, and proxy materials, helping users quickly understand transaction terms, clinical program disclosures, and changes in guidance without reading every page.
CorMedix Inc.’s Chief Executive Officer and director Joseph Todisco reported an equity award and related share transaction. On 01/23/2026, he received 225,900 restricted stock units, each representing one share of common stock, at a price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, a second transaction labeled code F covered 27,306 shares at $7.27 per share, leaving Todisco with 697,593 common shares held directly.
CorMedix Inc. director Myron Kaplan received an equity grant of 30,453 restricted stock units on January 26, 2026. The Form 4 shows these RSUs were awarded at a price of $0.00 per unit and will vest in full on January 26, 2027, subject to his continued service through that date.
Following this grant, Kaplan directly beneficially owned 231,487 shares of CorMedix common stock. The filing also notes additional indirect holdings of 20,000 shares held by his spouse and 10,000 shares held by his spouse as guardian for grandchildren, for which he expressly disclaims beneficial ownership.
CorMedix Inc. director Janet Dillione received an equity grant of 30,453 shares of common stock in the form of restricted stock units. The units were issued on January 26, 2026 at a stated price of $0.00 per share and represent a right to receive an equal number of common shares.
The restricted stock units will vest in full on January 26, 2027, conditioned on continued service through that date. Following this grant, Dillione beneficially owns 68,926 shares of CorMedix common stock in direct ownership.
CorMedix Inc. director Steven W. Lefkowitz reported receiving 30,453 shares of common stock on January 26, 2026 as restricted stock units granted at $0.00 per share. These units each represent one share of common stock and will vest in full on January 26, 2027, subject to his continued service.
After this grant, he beneficially owns 125,951 shares directly. He also has indirect beneficial ownership of 30,152 shares through the Wade Capital Corporation Money Purchase Plan, where he has voting and investment control, and 2,000 shares held by his spouse.
CorMedix Inc. director Alan W. Dunton received an equity award in the form of restricted stock units. On January 26, 2026, he was granted 30,453 restricted stock units of CorMedix common stock at a grant price of $0.00 per unit, increasing his beneficial ownership to 70,703 shares.
Each restricted stock unit represents the right to receive one share of common stock. The units will vest in full on January 26, 2027, provided he continues serving the company through the vesting date.
CorMedix Inc. director Stewart Robert A reported receiving 30,453 shares of common stock on a restricted basis at a price of $0.00 per share. Following this grant, he beneficially owns 66,453 CorMedix shares directly.
The award consists of restricted stock units issued on January 26, 2026. Each unit converts into one share of common stock and will vest in full on January 26, 2027, provided he continues to serve through the vesting date.
CorMedix Inc. director Duncan Gregory Scott received a grant of 30,453 restricted stock units (RSUs) of common stock on January 26, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting an equity compensation grant rather than a market purchase.
Each RSU represents the right to receive one share of CorMedix common stock. The RSUs will vest in full on January 26, 2027, provided Scott continues his service through the vesting date. After this grant, he beneficially owns 68,786 shares of CorMedix common stock in direct ownership form.
CorMedix Inc. director Janet Dillione reported a sale of company stock. On January 21, 2026, she sold 10,000 shares of CorMedix common stock at a weighted average price of $6.88 per share, in multiple trades executed between $6.85 and $6.90 per share. After this transaction, she beneficially owned 38,473 shares of CorMedix common stock directly.
The filing notes that the reported price is an average across several individual trades, and the director has agreed to provide detailed trade and pricing information to regulators, the company, or any security holder who requests it.
A person associated with CRMD has filed a notice to sell common stock under Rule 144. The filing shows a planned sale of 10,000 common shares through Merrill Lynch, with an aggregate market value of 68,502, on or about 01/21/2026 on the NASDAQ. The issuer had 78,789,045 shares of common stock outstanding. The seller acquired these 10,000 shares on 01/17/2026 via stock plan activity.
Over the prior three months, the same seller completed additional sales of common stock, including 34,000 shares for 407,030 on 12/09/2025, 46,657 shares for 465,169 on 12/02/2025, and 26,343 shares for 260,805 on 11/24/2025. This Form 144 is a notice of intent and does not by itself confirm that the planned shares have been sold.
CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, reported a Form 4 insider transaction involving company common stock. On 01/12/2026, a transaction coded "F" was reported for 5,794 shares of common stock at a price of $7.15 per share. Following this transaction, she directly beneficially owned 160,301 shares of CorMedix common stock. The filing notes that the transaction is being reported late due to an inadvertent administrative error.